Abeona Therapeutics Inc. (NASDAQ:ABEO) had its price objective increased by Maxim Group to $8.00 in a research note published on Wednesday morning.

Several other analysts also recently weighed in on the company. Rodman & Renshaw reiterated a buy rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research report on Friday, August 5th. Zacks Investment Research upgraded Abeona Therapeutics from a sell rating to a hold rating in a research report on Wednesday, July 20th. Cantor Fitzgerald began coverage on Abeona Therapeutics in a research note on Wednesday, September 7th. They set a buy rating and a $21.00 target price on the stock. Finally, FBR & Co reissued a buy rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Friday, August 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Abeona Therapeutics has an average rating of Buy and a consensus target price of $12.80.

Abeona Therapeutics (NASDAQ:ABEO) opened at 6.57 on Wednesday. The firm’s 50-day moving average price is $4.38 and its 200 day moving average price is $3.11. Abeona Therapeutics has a 52 week low of $2.05 and a 52 week high of $6.74. The company’s market capitalization is $220.39 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Equities research analysts expect that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of ABEO. BlackRock Fund Advisors boosted its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the last quarter. Finally, Sabby Management LLC boosted its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the last quarter. 19.95% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.